Clinical trials: Relapsed
Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Participants will be randomized to SCH 727965 or a comparator drug (bortezomib for mantle cell lymphoma [MCL] or alemtuzumab for B cell chronic lymphocytic leukemia [B CLL]).
- Trial name
- NCT00871546
- Testing
- SCH 727965, Bortezomib, Alemtuzumab
- Volunteers
- 8 people
- Sponsor
- Merck Sharp & Dohme LLC
B-cell Non-Hodgkin Lymphoma
Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma
This is an open-label, single-center Phase 1/2 study with a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2) in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).
- Trial name
- NCT04296461
- Testing
- Welgenaleucel
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- UWELL Biopharma
Relapsed and/or Refractory Multiple Myeloma
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
- Trial name
- NCT06153251
- Testing
- BMS-986453, Fludarabine, Cyclophosphamide
- Where
- 19 sites in United States, France and 2 more
- Volunteers
- 187 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Major Depressive Disorder
Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder
This study will demonstrate the efficacy of agomelatine (AGO178) 25 mg and 50 mg in the prevention of relapse in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT00467402
- Testing
- agomelatine
- Where
- 78 sites in United States
- Volunteers
- 644 people
- Sponsor
- Novartis
Solid Tumors
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT03634982
- Testing
- RMC-4630
- Where
- 12 sites in United States
- Volunteers
- 133 people
- Sponsor
- Revolution Medicines, Inc.
Leukemia, Lymphoma
VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00304005
- Testing
- laromustine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Vion Pharmaceuticals
Acute Myeloid Leukaemia Recurrent
The Effects of AMPC in the Treatments of Refractory or Relapsed AML
A private trial for evaluating the overall response rate contributed by AMPC in AML in refractory or relapsed AML
- Trial name
- AMPCAL (NCT03825146)
- Testing
- Autologous Multi-lineage Potential Cells (AMPC)
- Where
- Thailand
- Volunteers
- 10 people
- Sponsor
- Lai Corporation Pty. Ltd.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
A Phase 3 clinical trial to examine the efficacy of duvelisib monotherapy versus ofatumumab monotherapy in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
- Trial name
- NCT02004522
- Testing
- Duvelisib, Ofatumumab
- Where
- 92 sites in United States, Australia and 9 more
- Volunteers
- 319 people
- Sponsor
- SecuraBio
Cutaneous T-Cell Lymphoma
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
The purpose of this study is to compare the progression free survival of KW-0761 versus vorinostat for subjects with relapsed or refractory CTCL.
- Trial name
- NCT01728805
- Testing
- KW-0761, Vorinostat
- Where
- 73 sites in United States, Australia and 9 more
- Volunteers
- 372 people
- Sponsor
- Kyowa Kirin, Inc.
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
The primary aim of this study is to evaluate the impact of titration, analgesics, and 12 month telephone follow-up period from the B.E.T.A nurse program upon adherence to treatment with Betaseron in patients with a first clinical…
- Trial name
- START (NCT00461396)
- Testing
- Interferon-1beta (Betaseron, BAY86-5046)
- Where
- 19 sites in United States
- Volunteers
- 104 people
- Sponsor
- Bayer
Myelofibrosis
Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
The purpose of this study is to evaluate the efficacy and safety of 2 dose regimens of imetelstat in participants with intermediate-2 or high-risk myelofibrosis (MF) whose disease is relapsed after or is refractory to Janus…
- Trial name
- NCT02426086
- Testing
- Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg
- Where
- 72 sites in United States, Belgium and 9 more
- Volunteers
- 107 people
- Sponsor
- Geron Corporation
Chronic Lymphocytic Leukemia
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
This study evaluates the safety, pharmacokinetics, pharmacodynamics and efficacy of acalabrutinib and ceralasertib (known as AZD6738) when taken in combination.
- Trial name
- NCT03328273
- Testing
- Ceralasertib, Acalabrutinib
- Where
- 11 sites in Poland, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03893682
- Testing
- CG-806
- Where
- 30 sites in United States
- Volunteers
- 36 people
- Sponsor
- Aptose Biosciences Inc.
Diffuse Large B-Cell Lymphoma
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
The overall purpose of the study is to determine if MEDI-551, when used in combination with salvage chemotherapy, Ifosfamide-carboplatin-etoposide (ICE) or Dexamethasone-cytarabine (DHAP) in patients with relapsed or refractory…
- Trial name
- NCT01453205
- Testing
- MEDI-551 2 mg/kg, Rituximab, ICE
- Where
- 81 sites in United States, Canada and 9 more
- Volunteers
- 187 people
- Sponsor
- MedImmune LLC
Multiple Myeloma
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies
This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again…
- Trial name
- NCT06592222
- Testing
- Elranatamab, Standard of care
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
This is a single-arm, open, multicenter, phase 2 study to evaluate the efficacy, safety and pharmacokinetics of HYLM-122 in combination with cytarabine in Chinese subjects with FLT3 positive relapsed or refractory acute myeloid…
- Trial name
- NCT05241093
- Testing
- HYML-122; cytarabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Tarapeutics Science Inc.
Multiple Myeloma
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT03269136
- Testing
- PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 + lenalidomide
- Where
- 37 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Pfizer
Lymphoma, B-Cell
Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate inotuzumab ozogamicin in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma.
- Trial name
- NCT00867087
- Testing
- inotuzumab ozogamicin (CMC-544), rituximab
- Where
- 35 sites in United States, France and 4 more
- Volunteers
- 64 people
- Sponsor
- Pfizer
Solid Tumor, Hematologic Malignancy
A Study of DT2216 in Relapsed/Refractory Malignancies
A Phase 1, Open-Label, Dose Escalation, and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Subjects…
- Trial name
- NCT04886622
- Testing
- DT2216
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dialectic Therapeutics, Inc
Multiple Myeloma
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
The study consists of three parts: Part 1: The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent belantamab in participants with refractory multiple…
- Trial name
- DynaMMic-1 (NCT05714839)
- Testing
- Belantamab, Belantamab mafodotin, Pomalidomide
- Where
- 44 sites in United States, Argentina and 11 more
- Volunteers
- 123 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.